| September
2006, Minneapolis
ShoreView is pleased to announce the successful
sale of Axygen, Inc. to American
Capital Strategies. This transaction
highlights what has been a very successful
relationship between ShoreView and Axygen’s
founding shareholder and management. ShoreView
partnered with Axygen through a recapitalization
transaction in April 2003.
Prior to ShoreView’s investment, Axygen’s
owner was looking for a financial partner with
merger and acquisition expertise to help grow
the Company externally, and to provide capital
to support internal growth initiatives. ShoreView
structured a transaction that:
- Provided partial liquidity to the shareholders
- Allowed management to retain day-to-day
operating control of the business
- Created an ownership incentive plan for
key executives
- Gave the founder a substantial “second
bite at the apple” (opportunity for
second liquidity event)
ShoreView then worked with Axygen to:
- Build a new North American manufacturing
facility
- Make five add-on acquisitions
- Access low-cost manufacturing capacity
both in China and Poland
The results of this partnership were exceptional. Axygen
increased its market share worldwide, and its
revenue more than tripled and cash flow quadrupled
in three years.
About Axygen, Inc.
Axygen is a manufacturer of proprietary, high-end
plastic laboratory consumable products sold
into the life sciences industry. Products include
pipette tips, microtubes, filter tips, separation
columns, and various other plastic laboratory
consumables. The products are used by pharmaceutical
development labs, crime labs and academic labs.
About ShoreView Industries
ShoreView Industries, based in Minneapolis,
manages a $300 million private equity limited
partnership. ShoreView invests this partnership
in established, middle-market companies with
operations in North America, across a wide
range of industries. ShoreView structures a
variety of acquisition, recapitalization and
build-up transactions, typically in businesses
with revenues ranging between $20 million and
$150 million. |